| Different effects of naloxone on the growth hormone response to melatonin and pyridostigmine in normal men. | |
| | |
MedLine Citation:
|
PMID: 9667227 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The effect of melatonin (MEL) (12 mg orally), pyridostigmine (60 mg orally), the combination of MEL and pyridostigmine, or placebo on growth hormone (GH) secretion was tested in seven normal men. In addition, MEL tests and pyridostigmine tests were repeated after pretreatment with naloxone (1.2-mg bolus followed by intravenous [i.v.] infusion of 1.6 mg/h for 3 hours). Serum GH levels increased fivefold after MEL and sixfold after pyridostigmine administration. The concomitant administration of MEL did not change the GH response to pyridostigmine. In the presence of naloxone, the GH response to MEL was completely abolished, whereas naloxone did not modify the pyridostigmine-induced GH increase. These data suggest that MEL and pyridostigmine stimulate GH secretion through a common mechanism, which is probably represented by the inhibition of somatostatin activity. However, in contrast to pyridostigmine, the action of MEL appears to be exerted through a naloxone-sensitive opioid mediation. |
| | |
Authors:
|
V Coiro; R Volpi; L Capretti; N Giuliani; G Caffarri; R Colla; C Marchesi; P Chiodera |
Related Documents
:
|
7868307 - The role of plasma growth hormone, prolactin, triiodothyronine and tetraiodothyronine i... 3571017 - Determination of the temporal relationship between porcine growth hormone, serum igf-1 ... 8690107 - Age-dependent decrease in the growth hormone response to growth hormone-releasing hormo... 170027 - Hypothalamic hormone interaction in acromegaly. 3954457 - Intracellular and extracellular sulphydryl levels in rheumatoid arthritis. 8781637 - Determination of mineral, parathyroid hormone, and 6-keto-prostaglandin-f1 alpha levels... |
Publication Detail:
|
Type: Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Metabolism: clinical and experimental Volume: 47 ISSN: 0026-0495 ISO Abbreviation: Metab. Clin. Exp. Publication Date: 1998 Jul |
Date Detail:
|
Created Date: 1998-07-23 Completed Date: 1998-07-23 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0375267 Medline TA: Metabolism Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 814-6 Citation Subset: IM |
Affiliation:
|
Department of Internal Medicine, Institute of Psychiatry, School of Medicine, University of Parma, Italy. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Oral Adult Human Growth Hormone / biosynthesis*, blood, drug effects* Humans Infusions, Intravenous Injections, Intravenous Male Melatonin / administration & dosage*, antagonists & inhibitors Naloxone / administration & dosage* Pyridostigmine Bromide / administration & dosage*, adverse effects |
| Chemical | |
Reg. No./Substance:
|
101-26-8/Pyridostigmine Bromide; 12629-01-5/Human Growth Hormone; 465-65-6/Naloxone; 73-31-4/Melatonin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Reoxygenation injury affects isolated islet response to fatty acid stimulation.
Next Document: Effect of immunosuppression on kidney and serum insulin-like growth factor-I (IGF-I), IGF binding pr...